Search Results
1
Study Matches
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis
Atopic Dermatitis (AD): Phase 3 double-blinded study, 8 week study with 44 week long-term safety period with guaranteed study medicine. Topical cream. Male and females ≥ 2 Years to < 12 Years with AD
Atopic Dermatitis (AD), also known as eczema, is an inflammatory skin condition that can reoccur repeatedly. AD often causes itching and burning, skin flaking, and red bumps that can crust and open up.
The purpose of this study is to find out of the study medicine, ruxolitinib cream, can help with the treatment of AD.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
NCT04921969
Skin Conditions